Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C MacDougall

Showing results (291-300 of 373) with videos related to

Pageof 38
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 17, 2019
ErratumSharlene A Greenwood, Ellen Castle, Herolin Lindup, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2004
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?Francesco Locatelli, Pedro Aljama, Peter Barany, et al.
Clinical Nephrology|June 5, 2007
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyR Provenzano, A Besarab, I C Macdougall, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2015
A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patientsSunil Bhandari, Philip A Kalra, Jatin Kothari, et al.
Academic Pediatrics|August 11, 2024
A Randomized Trial of Virtual Reality Training to Improve Firearm Safety Counseling SkillsMichelle March, Matthew Zackoff, Jacob Fleck, et al.
BMC Nephrology|November 18, 2016
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trialMatthew A Roberts, Louis Huang, Darren Lee, et al.
Kidney Medicine|August 1, 2020
Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection RiskTomas Ganz, George R Aronoff, Carlo A J M Gaillard, et al.
Clinical Nephrology|July 1, 1997
Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patientsT B Drüeke, P Bárány, M Cazzola, et al.
The American Journal of Medicine|June 1, 1988
Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytomaI C Macdougall, C G Isles, H Stewart, et al.
Plos One|March 4, 2016
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis PatientsCarlo Barbieri, Elena Bolzoni, Flavio Mari, et al.
Pageof 38

Showing results (291-300 of 373) with videos related to

Sort By:
Pageof 38
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 17, 2019
ErratumSharlene A Greenwood, Ellen Castle, Herolin Lindup, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2004
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?Francesco Locatelli, Pedro Aljama, Peter Barany, et al.
Clinical Nephrology|June 5, 2007
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyR Provenzano, A Besarab, I C Macdougall, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2015
A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patientsSunil Bhandari, Philip A Kalra, Jatin Kothari, et al.
Academic Pediatrics|August 11, 2024
A Randomized Trial of Virtual Reality Training to Improve Firearm Safety Counseling SkillsMichelle March, Matthew Zackoff, Jacob Fleck, et al.
BMC Nephrology|November 18, 2016
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trialMatthew A Roberts, Louis Huang, Darren Lee, et al.
Kidney Medicine|August 1, 2020
Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection RiskTomas Ganz, George R Aronoff, Carlo A J M Gaillard, et al.
Clinical Nephrology|July 1, 1997
Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patientsT B Drüeke, P Bárány, M Cazzola, et al.
The American Journal of Medicine|June 1, 1988
Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytomaI C Macdougall, C G Isles, H Stewart, et al.
Plos One|March 4, 2016
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis PatientsCarlo Barbieri, Elena Bolzoni, Flavio Mari, et al.
Pageof 38